Friday, May 3, 2024
Home Biotech News 2022 Watch List Page 4

2022 Watch List

    Random

    Revive Therapeutics (RVVTF) Enters the Danger Zone.

    2022 Watch List Editor / Curator -
    What Danger You Ask? Danger #1, the FDA doesn't like the data, and you own the stock.

    Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...

    Biotech News Editor / Curator -
    Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings. Ardelyx ( NASDAQ: ARDX ) gained 35%...

    The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...

    2022 Watch List Editor / Curator -
    The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21. Revive Therapeutics (RVTTF), RedHill BioPharma...

    And We Have a $26.4 Billion Winning Trifecta!

    2022 Watch List Editor / Curator -
    THREE PREVIOUS WINNERS* Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired...

    He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!

    2022 Watch List Editor / Curator -
    Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.
    1234Page 4 of 4

    Latest article

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

    Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

    2024 Watch List Editor / Curator -
    CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.